Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effect of body mass index (BMI) on response to neoadjuvant therapy in human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC): Analysis from NeoALLTO trial
    Meeting Abstract

    Galli, G.; Bradbury, I.; Cinieri, S.; Agbor-Tarh, D.; De Braud, F. G. M.; Baselga, J.; Huober, J.; Fumagalli, D.; Sarp, S.; Piccart, M.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Pentsova, E.; Nolan, C.; Wolfe, J.; Mellinghoff, I. K.; Deangelis, L.
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Gavrilovic, I.; Kaley, T.; Nolan, C.; Omuro, A.; Wolfe, J.; Pentsova, E.; Hatzoglou, V.; Mellinghoff, I. K.; Deangelis, L.
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study
    Meeting Abstract

    Bryce, A. H.; Alumkal, J. J.; Armstrong, A.; Higano, C. S.; Iversen, P.; Sternberg, C. N.; Rathkopf, D. E.; Loriot, Y.; de Bono, J.; Tombal, B.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naive metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs)
    Meeting Abstract

    Carles, J.; Davis, I.; De Bono, J. S.; Fizazi, K.; Gerritsen, W.; Rathkopf, D. E.; Ryan, C. J.; Saad, F.; Steuber, T.; Wilding, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Cella, D.; Escudier, B.; Tannir, N.; Powles, T.; Donskov, F.; Peltola, K.; Schmidinger, M.; Heng, D.; Mainwaring, P.; Hammers, H.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from Alliance A031203 trial
    Meeting Abstract

    Choueiri, T. K.; Halabi, S.; Sanford, B.; Hahn, O.; Michaelson, M. D.; Walsh, M.; Olencki, T.; Picus, J.; Small, E. J.; Dakhil, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy
    Meeting Abstract

    Chu, Q. S. C.; Markman, B.; Leighl, N.; Krug, L.; Rudin, C.; Lathers, D.; Basciano, P.; Fracasso, P. M.; Kollia, G.; Phillips, P.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E-mutated (BRAFm) metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Corcoran, R. B.; Andre, T.; Yoshino, T.; Bendell, J. C.; Atreya, C. E.; Schellens, J. H. M.; Ducreux, M. P.; McRee, A.; Siena, S.; Middleton, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
    Meeting Abstract

    de Wit, R.; Kamat, A. M.; Bellmunt, J.; Choueiri, T. K.; Nam, K.; De Santis, M.; Dreicer, R.; Hahn, N. M.; Perini, R.; Siefker-Radtke, A. O.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save